Adalimumab-Atto

AMJEVITA

Tumor Necrosis Factor Blocker

NADAC/unit N/A

No Shortage PA Req: 6.4%

Adalimumab-Atto suppresses inflammation by blocking tumor necrosis factor, used in autoimmune conditions.

Covered Lives

Explore in the Ecosystem

rxsaver.aiCompare prices for Adalimumab-Atto drfinder.aiFind doctors who prescribe Adalimumab-Atto rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Adalimumab-Atto

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.